On the public citation graph
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
0 signed · 451 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/978-3-319-14151-0openalex-snapshot
PARP Inhibitors for Cancer Therapy
inferredcites →https://doi.org/10.1007/978-3-319-14151-0_19openalex-snapshot
PARP Inhibitor Resistance—What Is Beyond BRCA1 or BRCA2 Restoration?
inferredcites →https://doi.org/10.1007/s12253-010-9266-6openalex-snapshot
PARP and PARG Inhibitors—New Therapeutic Targets in Cancer Treatment
inferredcites →https://doi.org/10.1016/j.cell.2016.06.017openalex-snapshot
A Landscape of Pharmacogenomic Interactions in Cancer
inferredcites →https://doi.org/10.1016/j.celrep.2015.08.037openalex-snapshot
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
inferredcites →https://doi.org/10.1016/j.celrep.2018.04.046openalex-snapshot
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
inferredcites →https://doi.org/10.1016/j.critrevonc.2016.10.010openalex-snapshot
PARP inhibitor combination therapy
inferredcites →https://doi.org/10.1016/j.dnarep.2006.10.002openalex-snapshot
XRCC1 interactions with base excision repair DNA intermediates
inferredcites →https://doi.org/10.1016/j.dnarep.2015.04.008openalex-snapshot
The rise and fall of poly(ADP-ribose): An enzymatic perspective
inferredcites →https://doi.org/10.1016/j.dnarep.2017.02.010openalex-snapshot
Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase
inferredcites →https://doi.org/10.1016/j.ijrobp.2015.05.037openalex-snapshot
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
inferredcites →https://doi.org/10.1016/j.molcel.2016.01.019openalex-snapshot
PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining
inferredcites →https://doi.org/10.1016/j.molonc.2015.05.003openalex-snapshot
High level PHGDH expression in breast is predominantly associated with keratin 5‐positive cell lineage independently of malignancy
inferredcites →https://doi.org/10.1016/j.tig.2014.06.003openalex-snapshot
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
inferredcites →https://doi.org/10.1016/s0140-6736(10)60892-6openalex-snapshot
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
inferredcites →https://doi.org/10.1016/s0140-6736(10)60893-8openalex-snapshot
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
inferredcites →https://doi.org/10.1021/acschembio.6b00609openalex-snapshot
First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib
inferredcites →https://doi.org/10.1038/76095openalex-snapshot
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences
inferredcites →https://doi.org/10.1038/cr.2008.7openalex-snapshot
XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks
inferredcites →https://doi.org/10.1038/nature03443openalex-snapshot
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
inferredcites →https://doi.org/10.1038/nature03445openalex-snapshot
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
inferredcites →https://doi.org/10.1038/nature03482openalex-snapshot
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
inferredcites →https://doi.org/10.1038/nature06548openalex-snapshot
Resistance to therapy caused by intragenic deletion in BRCA2
inferredcites →https://doi.org/10.1038/nature07935openalex-snapshot
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
inferredcites →https://doi.org/10.1038/nature14328openalex-snapshot
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
inferredcites →https://doi.org/10.1038/nature18325openalex-snapshot
Replication fork stability confers chemoresistance in BRCA-deficient cells
inferredcites →https://doi.org/10.1038/ng747openalex-snapshot
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
inferredcites →https://doi.org/10.1038/nmeth.3047openalex-snapshot
Improved vectors and genome-wide libraries for CRISPR screening
inferredcites →https://doi.org/10.1038/nmeth.4535openalex-snapshot
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
inferredcites →https://doi.org/10.1038/nrm3376openalex-snapshot
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
inferredcites →https://doi.org/10.1038/nrm3935openalex-snapshot
Replication fork reversal in eukaryotes: from dead end to dynamic response
inferredcites →https://doi.org/10.1038/nsmb.2258openalex-snapshot
Topoisomerase I poisoning results in PARP-mediated replication fork reversal
inferredcites →https://doi.org/10.1038/nsmb.2501openalex-snapshot
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
inferredcites →https://doi.org/10.1056/nejmoa0900212openalex-snapshot
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
inferredcites →https://doi.org/10.1073/pnas.0406182101openalex-snapshot
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality
inferredcites →https://doi.org/10.1073/pnas.0702955104openalex-snapshot
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
inferredcites →https://doi.org/10.1073/pnas.0806092105openalex-snapshot
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
inferredcites →https://doi.org/10.1074/jbc.m114.624718openalex-snapshot
A Quantitative Assay Reveals Ligand Specificity of the DNA Scaffold Repair Protein XRCC1 and Efficient Disassembly of Complexes of XRCC1 and the Poly(ADP-ribose) Polymerase 1 by Poly(ADP-ribose) Glycohydrolase
inferredcites →https://doi.org/10.1074/mcp.m112.019786openalex-snapshot
Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer
inferredcites →https://doi.org/10.1083/jcb.200806068openalex-snapshot
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
inferredcites →https://doi.org/10.1083/jcb.201406099openalex-snapshot
Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells
inferredcites →https://doi.org/10.1083/jcb.201507042openalex-snapshot
TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity
inferredcites →https://doi.org/10.1093/bioinformatics/btp324openalex-snapshot
Fast and accurate short read alignment with Burrows–Wheeler transform
inferredcites →https://doi.org/10.1093/bioinformatics/btp352openalex-snapshot
The Sequence Alignment/Map format and SAMtools
inferredcites →https://doi.org/10.1093/bioinformatics/btp698openalex-snapshot
Fast and accurate long-read alignment with Burrows–Wheeler transform
inferredcites →https://doi.org/10.1093/bioinformatics/btr709openalex-snapshot
Robust rank aggregation for gene list integration and meta-analysis
inferredcites →https://doi.org/10.1093/bioinformatics/bts635openalex-snapshot
STAR: ultrafast universal RNA-seq aligner
inferredcites →https://doi.org/10.1093/bioinformatics/btt656openalex-snapshot
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
inferredcites →https://doi.org/10.1093/bioinformatics/btw354openalex-snapshot
MultiQC: summarize analysis results for multiple tools and samples in a single report
inferredcites →https://doi.org/10.1093/carcin/bgs132openalex-snapshot
PARPs and the DNA damage response
inferredcites →https://doi.org/10.1093/nar/gkt845openalex-snapshot
Identifying subgroup markers in heterogeneous populations
inferredcites →https://doi.org/10.1093/nar/gku936openalex-snapshot
Easy quantitative assessment of genome editing by sequence trace decomposition
inferredcites →https://doi.org/10.1101/gad.1331805openalex-snapshot
Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD + into a nuclear signal
inferredcites →https://doi.org/10.1101/gr.175141.114openalex-snapshot
DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly
inferredcites →https://doi.org/10.1101/sqb.2016.81.030924openalex-snapshot
Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer
inferredcites →https://doi.org/10.1124/jpet.113.210146openalex-snapshot
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
inferredcites →https://doi.org/10.1126/science.1243211openalex-snapshot
Break-Induced Replication Repair of Damaged Forks Induces Genomic Duplications in Human Cells
inferredcites →https://doi.org/10.1126/science.aam7344openalex-snapshot
PARP inhibitors: Synthetic lethality in the clinic
inferredcites →https://doi.org/10.1128/mcb.00990-12openalex-snapshot
BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8
inferredcites →https://doi.org/10.1158/0008-5472.can-08-0088openalex-snapshot
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
inferredcites →https://doi.org/10.1158/0008-5472.can-12-2753openalex-snapshot
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
inferredcites →https://doi.org/10.1158/0008-5472.can-15-3240openalex-snapshot
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-4953openalex-snapshot
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-1262openalex-snapshot
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
inferredcites →https://doi.org/10.1158/1535-7163.mct-13-0803openalex-snapshot
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
inferredcites →https://doi.org/10.1158/2159-8290.cd-12-0049openalex-snapshot
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
inferredcites →https://doi.org/10.1186/gb-2010-11-10-r106openalex-snapshot
Differential expression analysis for sequence count data
inferredcites →https://doi.org/10.1186/s12935-016-0333-2openalex-snapshot
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
inferredcites →https://doi.org/10.1186/s13059-014-0554-4openalex-snapshot
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
inferredcites →https://doi.org/10.1242/jcs.039115openalex-snapshot
Radiation-induced mitotic catastrophe in PARG-deficient cells
inferredcites →https://doi.org/10.12688/f1000research.8463.1openalex-snapshot
An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells
inferredcites →https://doi.org/10.1371/journal.pone.0061520openalex-snapshot
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
inferredcites →https://doi.org/10.1385/1-59259-973-7:287openalex-snapshot
Fast Micromethod DNA Single-Strand-Break Assay
inferredcites →https://doi.org/10.14806/ej.17.1.200openalex-snapshot
Cutadapt removes adapter sequences from high-throughput sequencing reads
inferredcites →https://doi.org/10.15252/msb.20145216openalex-snapshot
Measuring error rates in genomic perturbation screens: gold standards for human functional genomics
inferredcites →https://doi.org/10.2147/ott.s139336openalex-snapshot
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
inferredcites →https://doi.org/10.3389/fonc.2013.00228openalex-snapshot
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
inferredcites →https://doi.org/10.4161/cc.11.5.19482openalex-snapshot
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/1878-0261.12467openalex-snapshot
Exploiting DNA repair defects in colorectal cancer
inferred← citeshttps://doi.org/10.1002/1878-0261.12573openalex-snapshot
Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition‐mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2‐deficient cancer cells
inferred← citeshttps://doi.org/10.1002/1878-0261.13149openalex-snapshot
Deubiquitination of FBP1 by USP7 blocks FBP1–DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors
inferred← citeshttps://doi.org/10.1002/1878-0261.13224openalex-snapshot
Resistance to DNA repair inhibitors in cancer
inferred← citeshttps://doi.org/10.1002/1878-0261.13272openalex-snapshot
Exploring the genetic space of the DNA damage response for cancer therapy through CRISPR ‐based screens
inferred← citeshttps://doi.org/10.1002/1878-0261.70148openalex-snapshot
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
inferred← citeshttps://doi.org/10.1002/advs.202400140openalex-snapshot
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
inferred← citeshttps://doi.org/10.1002/advs.202502448openalex-snapshot
Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding
inferred← citeshttps://doi.org/10.1002/advs.77271openalex-snapshot
RSF1‐Dependent PAR Turnover Promotes 53BP1 Liquid Condensate Formation at DNA Damage Sites
inferred← citeshttps://doi.org/10.1002/aisy.202200247openalex-snapshot
Deep Learning‐Based Multiomics Data Integration Methods for Biomedical Application
inferred← citeshttps://doi.org/10.1002/ctm2.70244openalex-snapshot
HIF‐1α‐induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP‐ribosylation
inferred← citeshttps://doi.org/10.1002/gcc.23243openalex-snapshot
Exploration of poly (ADP‐ribose) polymerase inhibitor resistance in the treatment of BRCA1 /2‐mutated cancer
inferred← citeshttps://doi.org/10.1002/inmd.20220013openalex-snapshot
Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment
inferred← citeshttps://doi.org/10.1002/mco2.103openalex-snapshot
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
inferred← citeshttps://doi.org/10.1002/mco2.70314openalex-snapshot
PARP (Poly ADP‐ribose Polymerase) Family in Health and Disease
inferred← citeshttps://doi.org/10.1002/med.21886openalex-snapshot
Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective
inferred← citeshttps://doi.org/10.1002/mog2.70openalex-snapshot
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
inferred← citeshttps://doi.org/10.1002/stem.2929openalex-snapshot
Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy
inferred← citeshttps://doi.org/10.1007/978-3-031-09169-8_11openalex-snapshot
Targeted Molecular Therapy for Ovarian Cancer Patients
inferred← citeshttps://doi.org/10.1007/978-3-031-30065-3_2openalex-snapshot
Exploiting Cancer Synthetic Lethality in Cancer—Lessons Learnt from PARP Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-30065-3_3openalex-snapshot
Mechanisms of PARP Inhibitor Resistance
inferred← citeshttps://doi.org/10.1007/978-3-031-30065-3_4openalex-snapshot
Development of Homologous Recombination Functional Assays for Targeting the DDR
inferred← citeshttps://doi.org/10.1007/978-3-031-30065-3_8openalex-snapshot
Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-51712-9_17openalex-snapshot
Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives
inferred← citeshttps://doi.org/10.1007/978-3-031-58311-7_4openalex-snapshot
Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives
inferred← citeshttps://doi.org/10.1007/978-981-96-6779-6_2openalex-snapshot
Mechanisms Underlying the Resistance to Platinum and PARP Inhibitors in BRCA1/2-Mutated Tumors
inferred← citeshttps://doi.org/10.1007/s00210-024-03444-6openalex-snapshot
Potential promising of synthetic lethality in cancer research and treatment
inferred← citeshttps://doi.org/10.1007/s00404-020-05677-1openalex-snapshot
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
inferred← citeshttps://doi.org/10.1007/s10911-019-09436-0openalex-snapshot
The Eleventh ENBDC Workshop: Advances in Technology Help to Unveil Mechanisms of Mammary Gland Development and Cancerogenesis
inferred← citeshttps://doi.org/10.1007/s11033-026-12223-wopenalex-snapshot
Decoding PARP roles in breast cancer therapy resistance
inferred← citeshttps://doi.org/10.1007/s11864-023-01174-0openalex-snapshot
Targeting BRCA and PALB2 in Pancreatic Cancer
inferred← citeshttps://doi.org/10.1007/s12094-023-03191-9openalex-snapshot
Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1007/s12609-025-00582-5openalex-snapshot
Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors
inferred← citeshttps://doi.org/10.1007/s40265-023-01934-0openalex-snapshot
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
inferred← citeshttps://doi.org/10.1007/s40268-020-00301-8openalex-snapshot
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
inferred← citeshttps://doi.org/10.1007/s42764-020-00026-7openalex-snapshot
Targeting DNA repair pathways: mechanisms and potential applications in cancer therapy
inferred← citeshttps://doi.org/10.1007/s42764-022-00087-wopenalex-snapshot
Exploring the DNA damage response pathway for synthetic lethality
inferred← citeshttps://doi.org/10.1007/s42764-023-00100-wopenalex-snapshot
PARP molecular functions and applications of PARP inhibitors in cancer treatment
inferred← citeshttps://doi.org/10.1016/b978-0-323-95116-6.00005-0openalex-snapshot
Homologous repair deficiency and PARP inhibitors in cancer management
inferred← citeshttps://doi.org/10.1016/j.annonc.2020.02.008openalex-snapshot
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
inferred← citeshttps://doi.org/10.1016/j.bbadis.2024.167280openalex-snapshot
The fork remodeler helicase-like transcription factor in cancer development: all at once
inferred← citeshttps://doi.org/10.1016/j.bbadis.2024.167574openalex-snapshot
Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models
inferred← citeshttps://doi.org/10.1016/j.bbcan.2019.08.002openalex-snapshot
Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.bbcan.2021.188633openalex-snapshot
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway
inferred← citeshttps://doi.org/10.1016/j.bbcan.2024.189221openalex-snapshot
Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.bcp.2019.04.019openalex-snapshot
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
inferred← citeshttps://doi.org/10.1016/j.bcp.2019.06.004openalex-snapshot
Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.109546openalex-snapshot
Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?
inferred← citeshttps://doi.org/10.1016/j.biopha.2019.109661openalex-snapshot
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110204openalex-snapshot
Therapeutic applications of PARP inhibitors in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2019.06.007openalex-snapshot
Targeting DNA repair in breast cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2019.10.035openalex-snapshot
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers
inferred← citeshttps://doi.org/10.1016/j.canlet.2025.217599openalex-snapshot
PARP1 in melanoma: Mechanistic insights and implications for basic and clinical research
inferred← citeshttps://doi.org/10.1016/j.ccell.2019.02.004openalex-snapshot
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
inferred← citeshttps://doi.org/10.1016/j.cell.2020.09.055openalex-snapshot
An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation
inferred← citeshttps://doi.org/10.1016/j.celrep.2020.108068openalex-snapshot
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.109695openalex-snapshot
PARP1-mediated PARylation activity is essential for oligodendroglial differentiation and CNS myelination
inferred← citeshttps://doi.org/10.1016/j.celrep.2022.110421openalex-snapshot
Chromatin-associated orphan snoRNA regulates DNA damage-mediated differentiation via a non-canonical complex
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.112538openalex-snapshot
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.113113openalex-snapshot
The interplay of TARG1 and PARG protects against genomic instability
inferred← citeshttps://doi.org/10.1016/j.celrep.2024.114433openalex-snapshot
ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines
inferred← citeshttps://doi.org/10.1016/j.celrep.2024.114464openalex-snapshot
FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition
inferred← citeshttps://doi.org/10.1016/j.celrep.2025.116604openalex-snapshot
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
inferred← citeshttps://doi.org/10.1016/j.crmeth.2025.101270openalex-snapshot
Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102255openalex-snapshot
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
inferred← citeshttps://doi.org/10.1016/j.dnarep.2019.02.002openalex-snapshot
The role of dePARylation in DNA damage repair and cancer suppression
inferred← citeshttps://doi.org/10.1016/j.dnarep.2019.102654openalex-snapshot
Regulation of replication fork speed: Mechanisms and impact on genomic stability
inferred← citeshttps://doi.org/10.1016/j.dnarep.2021.103125openalex-snapshot
PARP1: Structural insights and pharmacological targets for inhibition
inferred← citeshttps://doi.org/10.1016/j.dnarep.2022.103382openalex-snapshot
The fast-growing business of Serine ADP-ribosylation
inferred← citeshttps://doi.org/10.1016/j.dnarep.2025.103824openalex-snapshot
Targeting dePARylation in cancer therapy
inferred← citeshttps://doi.org/10.1016/j.dnarep.2025.103830openalex-snapshot
PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy
inferred← citeshttps://doi.org/10.1016/j.dnarep.2025.103863openalex-snapshot
PARPs and ADP-ribosyl hydrolases in cancer therapy: From drug targets to biomarkers
inferred← citeshttps://doi.org/10.1016/j.drudis.2026.104803openalex-snapshot
Synthetic lethality and context-selective DNA-damage response dependencies: from genetic vulnerability to pharmacological translation
inferred← citeshttps://doi.org/10.1016/j.drup.2021.100744openalex-snapshot
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.drup.2023.100962openalex-snapshot
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1016/j.drup.2025.101287openalex-snapshot
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.114094openalex-snapshot
Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118507openalex-snapshot
Design, synthesis and biological evaluation of novel PARP inhibitors against acquired drug-resistance
inferred← citeshttps://doi.org/10.1016/j.gde.2019.03.001openalex-snapshot
Dissecting PARP inhibitor resistance with functional genomics
inferred← citeshttps://doi.org/10.1016/j.gde.2021.07.005openalex-snapshot
Serine ADP-ribosylation in DNA-damage response regulation
inferred← citeshttps://doi.org/10.1016/j.heliyon.2020.e03841openalex-snapshot
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
inferred← citeshttps://doi.org/10.1016/j.hoc.2022.08.018openalex-snapshot
Systemic Therapy for Hereditary Breast Cancers
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2024.125028openalex-snapshot
Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies
inferred← citeshttps://doi.org/10.1016/j.jbc.2023.105397openalex-snapshot
ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.01.026openalex-snapshot
PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy
inferred← citeshttps://doi.org/10.1016/j.mcpro.2025.101034openalex-snapshot
Multi-omics Characterization of Acquired Olaparib Resistance in BRCA1 and BRCA2 Mutant Breast Cancer Cell Lines
inferred← citeshttps://doi.org/10.1016/j.molcel.2020.04.035openalex-snapshot
Biomarker-Guided Development of DNA Repair Inhibitors
inferred← citeshttps://doi.org/10.1016/j.molcel.2021.04.028openalex-snapshot
Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease
inferred← citeshttps://doi.org/10.1016/j.molcel.2021.06.011openalex-snapshot
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
inferred← citeshttps://doi.org/10.1016/j.molcel.2021.09.005openalex-snapshot
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps
inferred← citeshttps://doi.org/10.1016/j.molcel.2022.02.021openalex-snapshot
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms
inferred← citeshttps://doi.org/10.1016/j.molmed.2021.04.010openalex-snapshot
Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance
inferred← citeshttps://doi.org/10.1016/j.neo.2024.101092openalex-snapshot
Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents
inferred← citeshttps://doi.org/10.1016/j.pbiomolbio.2021.01.004openalex-snapshot
DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy
inferred← citeshttps://doi.org/10.1016/j.phrs.2025.108058openalex-snapshot
Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer
inferred← citeshttps://doi.org/10.1016/j.semcancer.2019.02.005openalex-snapshot
Aberrations in DNA repair pathways in cancer and therapeutic significances
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.02.008openalex-snapshot
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
inferred← citeshttps://doi.org/10.1016/j.str.2024.09.006openalex-snapshot
PARG inhibition induces nuclear aggregation of PARylated PARP1
inferred← citeshttps://doi.org/10.1016/j.tcb.2019.07.008openalex-snapshot
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
inferred← citeshttps://doi.org/10.1016/j.tig.2018.12.002openalex-snapshot
Multiple Roles for Mono- and Poly(ADP-Ribose) in Regulating Stress Responses
inferred← citeshttps://doi.org/10.1016/j.tig.2019.03.008openalex-snapshot
Perspectives on PARPs in S Phase
inferred← citeshttps://doi.org/10.1016/j.tranon.2021.101012openalex-snapshot
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
inferred← citeshttps://doi.org/10.1016/j.tranon.2024.101893openalex-snapshot
Small molecule agents for triple negative breast cancer: Current status and future prospects
inferred← citeshttps://doi.org/10.1016/j.trecan.2021.08.007openalex-snapshot
Tackling PARP inhibitor resistance
inferred← citeshttps://doi.org/10.1016/j.trecan.2024.06.008openalex-snapshot
PARPi, BRCA, and gaps: controversies and future research
inferred← citeshttps://doi.org/10.1016/j.xgen.2024.100550openalex-snapshot
NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors
inferred← citeshttps://doi.org/10.1016/j.yexcr.2022.113163openalex-snapshot
Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation
inferred← citeshttps://doi.org/10.1016/j.ygyno.2020.08.035openalex-snapshot
Homologous recombination deficiency real-time clinical assays, ready or not?
inferred← citeshttps://doi.org/10.1016/j.ygyno.2022.10.011openalex-snapshot
Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance
inferred← citeshttps://doi.org/10.1016/j.ygyno.2025.08.010openalex-snapshot
State-of-the art in emerging therapeutics for ovarian cancer therapy
inferred← citeshttps://doi.org/10.1017/erm.2022.14openalex-snapshot
Exploring hypoxic biology to improve radiotherapy outcomes
inferred← citeshttps://doi.org/10.1017/erm.2024.17openalex-snapshot
ADP-ribose hydrolases: biological functions and potential therapeutic targets
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.8b01407openalex-snapshot
Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides
inferred← citeshttps://doi.org/10.1021/acschembio.5c00461openalex-snapshot
Discovery and Structural Optimization of 2-Hydrazinopyrimidin-4-one Analogs Inhibiting Human ADP-Ribosylhydrolase ARH3
inferred← citeshttps://doi.org/10.1038/s12276-021-00557-3openalex-snapshot
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
inferred← citeshttps://doi.org/10.1038/s41375-024-02269-9openalex-snapshot
DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients
inferred← citeshttps://doi.org/10.1038/s41388-021-01710-yopenalex-snapshot
Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
inferred← citeshttps://doi.org/10.1038/s41388-022-02427-2openalex-snapshot
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer
inferred← citeshttps://doi.org/10.1038/s41388-023-02782-8openalex-snapshot
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
inferred← citeshttps://doi.org/10.1038/s41388-025-03659-8openalex-snapshot
MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors
inferred← citeshttps://doi.org/10.1038/s41392-020-00358-6openalex-snapshot
Development of synthetic lethality in cancer: molecular and cellular classification
inferred← citeshttps://doi.org/10.1038/s41392-025-02271-2openalex-snapshot
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer
inferred← citeshttps://doi.org/10.1038/s41392-026-02954-4openalex-snapshot
Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation
inferred← citeshttps://doi.org/10.1038/s41416-020-01238-0openalex-snapshot
Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
inferred← citeshttps://doi.org/10.1038/s41416-023-02326-7openalex-snapshot
PARP inhibitors: enhancing efficacy through rational combinations
inferred← citeshttps://doi.org/10.1038/s41416-025-02963-0openalex-snapshot
SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells
inferred← citeshttps://doi.org/10.1038/s41418-024-01263-zopenalex-snapshot
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
inferred← citeshttps://doi.org/10.1038/s41419-026-08760-8openalex-snapshot
Nucleoporin TPR integrates MAPK signaling with mitogen-induced transcriptional programs
inferred← citeshttps://doi.org/10.1038/s41467-019-08859-xopenalex-snapshot
Emerging roles of eraser enzymes in the dynamic control of protein ADP-ribosylation
inferred← citeshttps://doi.org/10.1038/s41467-019-11048-5openalex-snapshot
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
inferred← citeshttps://doi.org/10.1038/s41467-019-13508-4openalex-snapshot
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death
inferred← citeshttps://doi.org/10.1038/s41467-020-14620-6openalex-snapshot
Genetic screens in isogenic mammalian cell lines without single cell cloning
inferred← citeshttps://doi.org/10.1038/s41467-020-17127-2openalex-snapshot
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
inferred← citeshttps://doi.org/10.1038/s41467-021-24224-3openalex-snapshot
The human nucleoporin Tpr protects cells from RNA-mediated replication stress
inferred← citeshttps://doi.org/10.1038/s41467-021-24361-9openalex-snapshot
Serine-linked PARP1 auto-modification controls PARP inhibitor response
inferred← citeshttps://doi.org/10.1038/s41467-021-26691-0openalex-snapshot
Zinc finger protein ZNF384 is an adaptor of Ku to DNA during classical non-homologous end-joining
inferred← citeshttps://doi.org/10.1038/s41467-023-35880-yopenalex-snapshot
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
inferred← citeshttps://doi.org/10.1038/s41467-024-48715-1openalex-snapshot
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours
inferred← citeshttps://doi.org/10.1038/s41467-025-58525-8openalex-snapshot
A noncanonical role of SAT1 enables anchorage independence and peritoneal metastasis in ovarian cancer
inferred← citeshttps://doi.org/10.1038/s41467-026-74950-9openalex-snapshot
FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability
inferred← citeshttps://doi.org/10.1038/s41523-022-00411-3openalex-snapshot
PARP inhibition in breast cancer: progress made and future hopes
inferred← citeshttps://doi.org/10.1038/s41556-020-00624-3openalex-snapshot
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
inferred← citeshttps://doi.org/10.1038/s41556-021-00807-6openalex-snapshot
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin
inferred← citeshttps://doi.org/10.1038/s41556-026-01961-5openalex-snapshot
Nucleophagy removes cytotoxic trapped PARP1
inferred← citeshttps://doi.org/10.1038/s41568-022-00518-6openalex-snapshot
Leveraging the replication stress response to optimize cancer therapy
inferred← citeshttps://doi.org/10.1038/s41568-022-00535-5openalex-snapshot
Targeting DNA damage response pathways in cancer
inferred← citeshttps://doi.org/10.1038/s41571-018-0114-zopenalex-snapshot
State-of-the-art strategies for targeting the DNA damage response in cancer
inferred← citeshttps://doi.org/10.1038/s41571-021-00532-xopenalex-snapshot
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
inferred← citeshttps://doi.org/10.1038/s41573-020-0076-6openalex-snapshot
Poly(ADP-ribose) polymerase inhibition: past, present and future
inferred← citeshttps://doi.org/10.1038/s41573-022-00558-5openalex-snapshot
Targeting replication stress in cancer therapy
inferred← citeshttps://doi.org/10.1038/s41580-020-0218-zopenalex-snapshot
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
inferred← citeshttps://doi.org/10.1038/s41586-022-05066-5openalex-snapshot
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
inferred← citeshttps://doi.org/10.1038/s41586-025-09414-zopenalex-snapshot
NASP modulates histone turnover to drive PARP inhibitor resistance
inferred← citeshttps://doi.org/10.1038/s41588-025-02448-zopenalex-snapshot
Insights from three decades of BRCA1/2 modeling in mice
inferred← citeshttps://doi.org/10.1038/s41598-023-30081-5openalex-snapshot
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer
inferred← citeshttps://doi.org/10.1038/s44318-024-00043-2openalex-snapshot
PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair
inferred← citeshttps://doi.org/10.1042/bst20180418openalex-snapshot
PARPs in genome stability and signal transduction: implications for cancer therapy
inferred← citeshttps://doi.org/10.1042/bst20220749openalex-snapshot
The function and regulation of ADP-ribosylation in the DNA damage response
inferred← citeshttps://doi.org/10.1042/bst20241633openalex-snapshot
‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancer
inferred← citeshttps://doi.org/10.1042/ebc20200013openalex-snapshot
Base excision repair and its implications to cancer therapy
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2023.08.001openalex-snapshot
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance
inferred← citeshttps://doi.org/10.1073/pnas.2009237117openalex-snapshot
FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination
inferred← citeshttps://doi.org/10.1073/pnas.2322689121openalex-snapshot
Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions
inferred← citeshttps://doi.org/10.1073/pnas.2426743122openalex-snapshot
BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function
inferred← citeshttps://doi.org/10.1073/pnas.2513742123openalex-snapshot
Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion
inferred← citeshttps://doi.org/10.1080/10428194.2020.1824067openalex-snapshot
MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation
inferred← citeshttps://doi.org/10.1080/13543776.2021.1886275openalex-snapshot
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)
inferred← citeshttps://doi.org/10.1080/13543784.2021.1939305openalex-snapshot
Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies
inferred← citeshttps://doi.org/10.1080/13543784.2022.2067527openalex-snapshot
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
inferred← citeshttps://doi.org/10.1080/14656566.2021.1952181openalex-snapshot
Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancer
inferred← citeshttps://doi.org/10.1080/14728222.2019.1654458openalex-snapshot
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers
inferred← citeshttps://doi.org/10.1080/14737140.2020.1797497openalex-snapshot
The emerging role of PARP inhibitors in prostate cancer
inferred← citeshttps://doi.org/10.1080/14737140.2024.2393251openalex-snapshot
Strategies for the prevention or reversal of PARP inhibitor resistance
inferred← citeshttps://doi.org/10.1080/14737140.2024.2398494openalex-snapshot
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes
inferred← citeshttps://doi.org/10.1080/15384047.2021.2024414openalex-snapshot
Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion
inferred← citeshttps://doi.org/10.1080/15384101.2019.1618542openalex-snapshot
DNA double-strand break repair pathway choice - from basic biology to clinical exploitation
inferred← citeshttps://doi.org/10.1080/17568919.2025.2561467openalex-snapshot
Design, development, and therapeutic applications of PARP-1 selective inhibitors
inferred← citeshttps://doi.org/10.1083/jcb.202002175openalex-snapshot
Interferon-stimulated gene 15 accelerates replication fork progression inducing chromosomal breakage
inferred← citeshttps://doi.org/10.1084/jem.20211743openalex-snapshot
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
inferred← citeshttps://doi.org/10.1093/annonc/mdz192openalex-snapshot
A decade of clinical development of PARP inhibitors in perspective
inferred← citeshttps://doi.org/10.1093/jjco/hyac065openalex-snapshot
Current trends in chemotherapy for advanced ovarian cancer
inferred← citeshttps://doi.org/10.1093/nar/gkac948openalex-snapshot
PARP1 proximity proteomics reveals interaction partners at stressed replication forks
inferred← citeshttps://doi.org/10.1093/nar/gkae439openalex-snapshot
The loss of DNA polymerase epsilon accessory subunits POLE3–POLE4 leads to BRCA1-independent PARP inhibitor sensitivity
inferred← citeshttps://doi.org/10.1093/nar/gkae756openalex-snapshot
PARP1-TRIM44-MRN loop dictates the response to PARP inhibitors
inferred← citeshttps://doi.org/10.1093/nar/gkaf1398openalex-snapshot
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells
inferred← citeshttps://doi.org/10.1093/nar/gkaf544openalex-snapshot
USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance
inferred← citeshttps://doi.org/10.1093/narcan/zcaa024openalex-snapshot
Regulation and pharmacological targeting of RAD51 in cancer
inferred← citeshttps://doi.org/10.1093/narcan/zcad043openalex-snapshot
The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors
inferred← citeshttps://doi.org/10.1093/narcan/zcae030openalex-snapshot
Intrinsic PARG inhibitor sensitivity is mimicked by TIMELESS haploinsufficiency and rescued by nucleoside supplementation
inferred← citeshttps://doi.org/10.1093/procel/pwaf091openalex-snapshot
Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching
inferred← citeshttps://doi.org/10.1096/fj.202403378ropenalex-snapshot
Poly (ADP‐Ribose) Glycohydrolase‐Dependent dePARylation of PCNA Is Essential for DNA Replication
inferred← citeshttps://doi.org/10.1097/cco.0000000000000516openalex-snapshot
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer
inferred← citeshttps://doi.org/10.1097/gco.0000000000000600openalex-snapshot
Mechanisms of PARP inhibitor resistance in ovarian cancer
inferred← citeshttps://doi.org/10.1098/rsob.180080openalex-snapshot
Mouse models in the era of large human tumour sequencing studies
inferred← citeshttps://doi.org/10.1098/rsob.190041openalex-snapshot
ADP-ribosylation signalling and human disease
inferred← citeshttps://doi.org/10.1098/rsob.220118openalex-snapshot
Opinion: PARP inhibitors in cancer—what do we still need to know?
inferred← citeshttps://doi.org/10.1101/2020.07.13.199968openalex-snapshot
PARG inhibition induces replication catastrophe in ovarian cancer cells with down-regulated DNA replication genes
inferred← citeshttps://doi.org/10.1101/2021.03.24.436323openalex-snapshot
Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps
showing the first 200 of 373 · page through all 373
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.